Discovery offers new treatment for epilepsy

November 20, 2012

New drugs derived from components of a specific diet used by children with severe, drug-resistant epilepsy could offer a new treatment, according to research published today in the journal Neuropharmacology.

Scientists from Royal Holloway, in collaboration with University College London, have identified specific fatty acids that have potent antiepileptic effects, which could help control seizures in children and adults.

The discovery could lead to the replacement of the ketogenic , which is often prescribed for children with severe drug-resistant epilepsy. The high fat, is thought to mimic aspects of starvation by forcing the body to burn fats rather than carbohydrates. Although often effective, the diet has attracted criticism, as side effects can be significant and potentially lead to constipation, hypoglycaemia, retarded growth and .

By pinpointing fatty acids in the ketogenic diet that are effective in controlling epilepsy, researchers hope that they can develop a pill for children and adults that could provide similar epilepsy control, but lacks the side effects of the diet.

Professor Robin Williams from the Centre of at Royal Holloway said: "This is an important breakthrough. The family of medium chain fatty acids that we have identified provide an exciting new field of research with the potential of identifying, stronger, and safer epilepsy treatments."

The study tested a range of fatty acids found in the against an established epilepsy treatment. Researchers found that not only did some of the fatty acids outperform the drug in controlling seizures, they also had fewer side effects.

Professor Matthew Walker from the Institute of Neurology, University College London said: "Epilepsy affects over 50 million people worldwide and approximately a third of these people have epilepsy that is not adequately controlled by our present treatments. This discovery offers a whole new approach to the treatment of drug-resistant epilepsies in children and adults."

The research also builds on work funded by the NC3Rs in which most of the animal testing normally used in drug development for epilepsy has been replaced by using a simple amoeba to initially screen and identify improved treatments.

Professor Williams added: "Animals are often used in the search for new treatments. Our work provides a new approach, helping us to reduce reliance on animals and provide potential major improvements in human health."

The specific identified in this work are the subject of a patent application, and Royal Holloway is seeking commercial collaborators to pursue the potential for new drug development.

Related Stories

Recommended for you

Research grasps how the brain plans gripping motion

July 28, 2015

With the results of a new study, neuroscientists have a firmer grasp on the way the brain formulates commands for the hand to grip an object. The advance could lead to improvements in future brain-computer interfaces that ...

New research rethinks how we grab and hold onto objects

July 28, 2015

It's been a long day. You open your fridge and grab a nice, cold beer. A pretty simple task, right? Wrong. While you're debating between an IPA and a lager, your nervous system is calculating a complex problem: how hard to ...

It don't mean a thing if the brain ain't got that swing

July 27, 2015

Like Duke Ellington's 1931 jazz standard, the human brain improvises while its rhythm section keeps up a steady beat. But when it comes to taking on intellectually challenging tasks, groups of neurons tune in to one another ...

Sleep makes our memories more accessible, study shows

July 27, 2015

Sleeping not only protects memories from being forgotten, it also makes them easier to access, according to new research from the University of Exeter and the Basque Centre for Cognition, Brain and Language. The findings ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.